Zacks Investment Research on MSN
Hims & Hers expands weight-management program to the United Kingdom
Hims & Hers HIMS recently announced that it is expanding access to its comprehensive Weight Loss Program to customers in the ...
Zacks Investment Research on MSN
Investors heavily search Hims & Hers Health, Inc. (HIMS): Here is what you need to know
Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea ...
Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk. The bundle will offer Novo Nordisk’s ...
Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...
The trajectory of well-known health and wellness platform Hims & Hers is one that most entrepreneurs and investors would hope for. Not even six years old, the company has for the most part experienced ...
The market is just starting to notice the great things this small-cap stock has been doing for a while now. It often feels like you've missed the boat when you sit there reading about another stock ...
The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...
Hims & Hers stock is on the upswing after the company secured a weight-loss drug partnership. Hims & Hers is acquiring its way into Europe and wants to build more personalized drugs for its telehealth ...
Hims and Hers first announced its expansion into Canada in early July, taking the opportunity as Danish pharmaceutical giant ...
Health platform Hims & Hers Health Inc. announced Monday that it's rolling out injectable weight-loss drugs that cost a fraction of the price of competitors Wegovy and Ozempic. Hims & Hers says its ...
The telehealth company is being criticized for its Super Bowl weight loss commercial. (Hims & Hers via YouTube) During the Super Bowl, Hims & Hers Health aired a commercial called “Sick of the System.
Hims & Hers Health Inc. (NYSE: HIMS), a telehealth company with a $6.1 billion valuation, has been a remarkable growth story, especially over the past year. The stock climbed an astounding 215% in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback